Dehydroepiandrosterone (DHEA) replacement in postmenopausal women: Present status and future promise

Peter R. Casson, Peter J. Hornsby, Husam F. Ghusn, John E. Buster

Resultado de la investigación: Articlerevisión exhaustiva

4 Citas (Scopus)


Objective: Age-related declines in dehydroepiandroserone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S) have been postulated to aggravate some diseases of the elderly. As a result, DHEA supplementation is often touted as the "fountain of youth" and is being used widely in an unregulated fashion, without evidence of efficacy or safety. Design: Review of the English-language literature. This review addresses DHEA replacement, touching on issues of bioavailability and possible beneficial effects. Safety concerns are also addressed. Conclusions: At present, we believe that DHEA replacement is not suitable for widespread clinical use; however, the potential for future hormonal therapy of aging with this compound is such that further investigation is certainly warranted.

Idioma originalEnglish (US)
Páginas (desde-hasta)225-231
Número de páginas7
EstadoPublished - dic 1 1997
Publicado de forma externa

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Profundice en los temas de investigación de 'Dehydroepiandrosterone (DHEA) replacement in postmenopausal women: Present status and future promise'. En conjunto forman una huella única.

Citar esto